Research progress of TERT promoter mutation in thyroid cancer

Abstract

Abstract:

Thyroid cancer is a common endocrine malignancy and its morbidity raised rapidly in recent years. The association between TERT promoter mutations (C228T,C250T) and clinical outcomes have been investigated since they were confirmed in thyroid cancer (including differentiated thyroid cancer and anaplastic thyroid cancer) in 2013. Most studies suggest the mutations are associated with thyroid cancer, the clinical outcomes and poor prognosis. The two mutations are considered to be oncogenic mutations. In order to provide a new sight into the research of TERT promoter mutation, diagnosis and treatment of thyroid cancer, we summarized the incidence of TERT promoter mutation in different types of thyroid cancer and the clinical relevance of these mutations.

Key words: thyroid cancer, telomerase reverse transcriptase, promoter mutation

CLC Number:

R736.1

TANG Xinyue, SHI Feng, LI Cuilin, LIU Jianqiu, LI Zhi. Research progress of TERT promoter mutation in thyroid cancer[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(3): 350-354.

References

［1］Fallet E, Jolivet P, Soudet J, et al. Length-dependent processing of telomeres in the absence of telomerase［J］. Nucleic Acids Res, 2014, 42(6): 3648-3665.
［2］Kim NW, Piatyszek MA, Prowse KR, et al. Specific association of human telomerase activity with immortal cells and cancer［J］. Science, 1994, 266(5193): 2011-2015.
［3］李小宁，杨正海，李静，等. 不同基因型丙型肝炎病毒非结构蛋白NS3对端粒酶活性的研究［J］. 中国临床药理学与治疗学, 2015, 20(2): 534-538.
［4］Horn S, Figl A, Rachakonda PS, et al. TERT promoter mutations in familial and sporadic melanoma［J］. Science, 2013, 339(6122): 959-961.
［5］Cong YS, Wen J, Bacchetti S. The human telomerase catalytic subunit hTERT: Organization of the gene and characterization of the promoter［J］. Hum Mol Genet, 1999, 8(1): 137-142.
［6］Ramlee MK, Wang J, Toh WX, et al. Transcription regulation of the human telomerase reverse transcriptase (hTERT) gene［J］. Genes (Basel), 2016, 7(8): pii: E50.
［7］Vinagre J, Almeida A, Populo H, et al. Frequency of TERT promoter mutations in human cancers［J］. Nat Commun, 2013, 4: 2185.
［8］Haugen BR,Alexander EK,Bible KC,et al.2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer:The American thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer［J］.Thyroid,2016,26(1):1-133.
［9］Hundahl SA, Fleming ID, Fremgen AM, et al. A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995 ［see commetns］［J］. Cancer-Am Cancer Soc, 1998, 83(12): 2638-2648.
［10］Liu X, Bishop J, Shan Y, et al. Highly prevalent TERT promoter mutations in aggressive thyroid cancers［J］. Endocr Relat Cancer, 2013, 20(4): 603-610.
［11］Landa I, Ganly I, Chan TA, et al. Frequent somatic TERT promoter mutations in thyroid cancer: Higher prevalence in advanced forms of the disease［J］. J Clin Endocrinol Metab, 2013, 98(9): E1562-1566.
［12］Melo M, Da RA, Vinagre J, et al. TERT promoter mutations are a major indicator of poor outcome in differentiated thyroid carcinomas［J］. J Clin Endocrinol Metab, 2014, 99(5): E754-765.
［13］Qasem E, Murugan AK, Al-Hindi H, et al. TERT promoter mutations in thyroid cancer: A report from a Middle Eastern population［J］. Endocr Relat Cancer, 2015, 22(6): 901-908.
［14］Liu R, Xing M. TERT promoter mutations in thyroid cancer［J］. Endocr-Relat Cancer, 2016,23(3): R143-155.
［15］Wang N, Liu T, Sofiadis A, et al. TERT promoter mutation as an early genetic event activating telomerase in follicular thyroid adenoma (FTA) and atypical FTA［J］. Cancer-Am Cancer Soc, 2014, 120(19): 2965-2979.
［16］Alzahrani AS, Alsaadi R, Murugan AK, et al. TERT promoter mutations in thyroid cancer［J］. Hormones and Cancer, 2016, 7(3): 165-177.
［17］de Biase D, Gandolfi G, Ragazzi M, et al. TERT promoter mutations in papillary thyroid microcarcinomas［J］. Thyroid, 2015, 25(9): 1013-1019.
［18］Ballester LY, Sarabia SF, Sayeed H, et al. Integrating molecular testing in the diagnosis and management of children with thyroid lesions［J］. Pediatr Dev Pathol, 2016, 19(2): 94-100.
［19］Muzza M, Colombo C, Rossi S, et al. Telomerase in differentiated thyroid cancer: Promoter mutations, expression and localization［J］. Mol Cell Endocrinol, 2015, 399: 288-295.
［20］Xing M, Liu R, Liu X, et al. BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence［J］. J Clin Oncol, 2014, 32(25): 2718-2726.
［21］Liu X, Qu S, Liu R, et al. TERT promoter mutations and their association with BRAF V600E mutation and aggressive clinicopathological characteristics of thyroid cancer［J］. J Clin Endocrinol Metab, 2014, 99(6): E1130-1136.
［22］Liu T, Wang N, Cao J, et al. The age- and shorter telomere-dependent TERT promoter mutation in follicular thyroid cell-derived carcinomas［J］. Oncogene, 2014, 33(42): 4978-4984.
［23］Shi X, Liu R, Qu S, et al. Association of TERT promoter mutation 1,295,228 C>T with BRAF V600E mutation, older patient age, and distant metastasis in anaplastic thyroid cancer［J］. J Clin Endocrinol Metab, 2015, 100(4): E632-637.
［24］Kim TH, Kim YE, Ahn S, et al. TERT promoter mutations and long-term survival in patients with thyroid cancer［J］. Endocr Relat Cancer, 2016, 23(10):813-823.
［25］Gandolfi G, Ragazzi M, Frasoldati A, et al. TERT promoter mutations are associated with distant metastases in papillary thyroid carcinoma［J］. Eur J Endocrinol, 2015, 172(4): 403-413.
［26］Jin L, Chen E, Dong S, et al. BRAF and TERT promoter mutations in the aggressiveness of papillary thyroid carcinoma: A study of 653 patients［J］. Oncotarget, 2016, 7(14): 18346-18355.
［27］Lee SE, Hwang TS, Choi YL, et al. Prognostic significance of TERT promoter mutations in papillary thyroid carcinomas in a BRAF(V600E) Mutation-Prevalent population［J］. Thyroid, 2016, 26(7): 901-910.
［28］Li Y, Cheng HS, Chng WJ, et al. Activation of mutant TERT promoter by RAS-ERK signaling is a key step in malignant progression of BRAF-mutant human melanomas［J］. Proc Natl Acad Sci U S A, 2016, 113(50): 14402-14407.

[1]	CHEN Wenjie, WANG Yabing, CHEN Xiaolin, REN Junling, ZHAO Wanjun, CHEN bin. Advances in the study of iodine-resistant differentiated thyroid cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(1): 116-120.
[2]	SU Shan, ZHANG Di, WANG Qiangmei, ZHEN Donghu. Correlation between vitamin D and thyroid disease [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(1): 94-100.